Q2 earnings highlight a wider net loss but improved per share figures

Avalo Therapeutics (AVTX) reported second quarter and first half 2026 results, with higher net losses than a year earlier. Loss per share figures improved, which gives investors a mixed picture to assess.

Avalo Therapeutics shares trade at US$19.71 after a recent 20.99% 90 day share price return and a 121.59% 1 year total shareholder return, although the 5 year total shareholder return is down 99.77%. This suggests momentum has been strong in the short term but weak over a longer horizon.

If Avalo Therapeutics has you looking closer at high risk biotech ideas, you may also want to see what is moving in healthcare related AI with the 40 healthcare AI stocks

Avalo Therapeutics has run hard in the past year, yet long term returns remain deeply negative and recent results still show sizeable losses. Is it worth paying up today, or does patience for a lower entry make more sense?

Preferred Price-to-Book of 2.4x for Avalo Therapeutics: Is it justified?

Avalo Therapeutics trades on a P/B of 2.4x, which screening data flags as good value against both its peer group and the wider US biotechs industry.

The price to book ratio compares the company’s market value to its net assets on the balance sheet. For a clinical stage biotech like Avalo Therapeutics that is loss making and has minimal revenue of $59K, this measure often reflects what investors are willing to pay today for the company’s research pipeline and future potential rather than current earnings.

Here, the P/B of 2.4x sits below the peer average of 3.8x and in line with the broader US biotechs industry at 2.4x. That signals the market is assigning Avalo Therapeutics a valuation that is lower than similar companies by this yardstick, while still broadly consistent with sector norms.

Because there is no reliable fair ratio estimate, the comparison stops at peers and industry, rather than pointing to any model based target level the P/B could move toward.

Result: Price-to-book of 2.4x (UNDERVALUED)

However, Avalo Therapeutics still carries clinical and funding risk, since AVTX-009 is only in phase 2 and the company reports a net loss of US$100.333m.

Another view on Avalo Therapeutics using the SWS DCF model

The earlier P/B workup suggests Avalo Therapeutics looks inexpensive against peers. The SWS DCF model points the other way. It estimates future cash flow value at about $0.17 per share versus a $19.95 share price, which screens as very overvalued on that framework. Which benchmark should carry more weight for you right now?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Avalo Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals around Avalo Therapeutics, it makes sense to check the underlying data rather than rely on headline metrics alone. If you want to understand what could go wrong before you commit fresh capital, start with the company’s 4 important warning signs.

Looking for more investment ideas beyond Avalo Therapeutics?

If Avalo Therapeutics has sharpened your focus on stock selection, do not stop here. A few targeted stock lists could surface ideas that fit your style.

• Target potential value opportunities by scanning companies that currently screen as attractively priced with the 53 high quality undervalued stocks.
• Strengthen your income stream by checking out stocks that feature resilient payout profiles through the 10 dividend fortresses.
• Prioritise financial resilience by focusing on companies highlighted in the solid balance sheet and fundamentals stocks screener (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.